Skip to content

The efficacy of tonifying Kidney and benefiting Marrow method for the a-synuclein diseases (PD, MSA) on the theory of treating different diseases with the same treatment and discussion of TCM pathogenesis

The efficacy of tonifying Kidney and benefiting Marrow method for the a-synuclein diseases (PD, MSA) on the theory of treating different diseases with the same treatment and discussion of TCM pathogenesis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004930
Enrollment
Unknown
Registered
2021-06-09
Start date
2020-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multisystem atrophy, Parkinson's disease

Interventions

Sponsors

Dongfang Hospital of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. According to the diagnosis of PD and MSA, the patients aged 30 to 80 years; 2. All the included cases were selected as mild and moderate patients; 3. According to Hoya classification (HY), the patients with HY 3 were selected as PD patients, and the PD evaluation time was selected as the opening time, 1.5-3 hours after taking medicine; 4. According to the unified multiple system atrophy assessment scale (UMSARS-IV), the patients with UMSARS-IV <=3 were selected as MSA patients Patients in the hospital.

Exclusion criteria

Exclusion criteria: 1. Nervous system examination showed that there were brain atrophy or dementia caused by systemic diseases or other clear reasons, such as severe depression, cerebrovascular disease, poisoning and metabolic diseases; 2. Obvious slowing down of vertical rapid scanning or vertical supranuclear gaze paralysis; 3. Evidence of local cerebral cortex damage, such as aphasia, allopathy, parietal lobe dysfunction; pregnant women, with severe heart, liver and kidney diseases that who can not complete the scale and related examinations.

Design outcomes

Primary

MeasureTime frame
UMSARS-I, II;MSA-NMSS;TCM Syndrome Scale of Kidney Deficiency and Pulp Reduction;Hoehn-Yahr (H-Y) staging score;NMSS;DTI, fMRI (BOLD);unified Parkinson disease rating scale, UPDRS-U-3;

Countries

China

Contacts

Public ContactChen Zhigang

Beijing University of Chinese Medicine

chenzhigang64@126.com+86 010 67689776

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026